There is a clean version of this story circulating and I am going to take it apart before I build anything on it.
The clean version goes like this. China restricted germanium exports. Germanium is the material every infrared lens is made from. LightPath Technologies makes BlackDiamond, a germanium-free glass, and is therefore the only way for Western defense programs to keep building thermal imagers. Buy the stock.
Two of those sentences are true. The one in the middle is not, and LightPath says so itself, in its own annual report, in writing.
What is left after you remove it is a more interesting company than the story implies, sitting on top of two disclosures made in the last nine days that nobody has written about.
First, the part of the story that is wrong
BlackDiamond BD6 is arsenic selenide, As40Se60. That is not a proprietary formula. It is a well known chalcogenide composition.
VITRON Spezialwerkstoffe in Jena, Germany publishes a glass called IG 6. Its composition is As40Se60. The same material. SCHOTT sells the same family as IRG 22 through IRG 27. Umicore sells GASIR.
You do not have to take my word for it, because LightPath's own fiscal 2025 annual report says it plainly:
"Some of these materials such as BD6 and BD2, are generic, and are produced by at least two other companies. The crown jewels of our materials, the BDNL type, are exclusive to us."
That is the company telling you the material at the center of the popular thesis is generic. Any bull case resting on BD6 being the only germanium substitute is going to meet that sentence eventually, and it will lose.
So what is actually defensible? Four things, and they are better than the chemistry claim because they are harder to copy.
Domestic melt capacity. Making the glass in the United States is not the same as knowing the formula. VITRON is German, SCHOTT is German, Umicore is Belgian. For a US defense program with domestic sourcing requirements, where the glass is melted is the qualifying fact, not what is in it.
A government-funded qualification path. This is the piece I find most persuasive and it is completely absent from coverage. The Defense Logistics Agency has paid LightPath twice, under two sequential contracts, specifically to qualify chalcogenide as a defense material:
Material qualification is the actual barrier to entry in defense optics. Not the recipe. The recipe is in the literature. What takes years is getting a material onto a qualified list and into a program of record, and the US government is underwriting LightPath's path through that process. That is public, dated, and durable in a way a glass composition is not.
Molding yield. Chalcogenide is precision moulded rather than diamond turned. That process knowledge is real and it does not transfer with a datasheet.
Vertical integration into cameras, via the G5 Infrared acquisition, which is where most of the value and most of the accounting complexity now sits.
And the honest technical caveat. Chalcogenide is not a straight drop-in for germanium. Transmission band and thermal drift behaviour differ. Some designs substitute cleanly and some require a redesign. Anyone telling you it is a simple swap has not read a datasheet.
The disclosure from nine days ago that nobody has read
On July 22, LightPath filed twenty two post-effective amendments and seven S-8 post-effective amendments. On July 23, twenty two effectiveness notices came back. Twenty two of anything in one day gets my attention.
Most of it is housekeeping. The cover pages say removal from registration of securities that were not sold.
But buried in it is something live. Registration number 333-262768, filed in February 2022, registered $75.8 million of shelf capacity plus $25.2 million under an at-the-market sales agreement with A.G.P. and Alliance Global Partners. Deregistering it formally terminates that at-the-market facility.
That matters more than it sounds. An at-the-market programme is a machine that sells stock into the market quietly, every day, at whatever the bid is. Turning it off means future capital raises have to be visible, discrete block deals rather than a continuous drip. For a company with LightPath's history of returning to the equity market, replacing silent supply with announced supply is a structural improvement in how shareholders get treated, and nobody has noticed it happened.
The remaining live vehicles are the December 2025 primary shelf and two resale shelves.
The disclosure from eight days ago that is genuinely uncomfortable
On July 23, LightPath agreed to sell one hundred percent of its Chinese subsidiary, LightPath Zhenjiang Optical Instrumentation, to a company called Hengtu Optical Technology in Nanjing.
Read the counterparty description from the filing carefully:
owned by the Purchaser Representative (Mr. Leo Zheng) and certain members of the Company's current management team.
LightPath's own management is on the buying side.
The price is $4.5 million paid over five years, minimum $500,000 per year, with 4 percent financing interest per installment and 7 percent on default, unsecured on the public record. LightPath retains a board observer seat and licenses over the trademarks for five years along with product drawings, tooling, moulds, process documentation, technology and know-how. There is a five year exclusive supply agreement, so LightPath keeps buying from the factory it sold.
Those China operations generated roughly $4.5 million per year of third party revenue. So LightPath is selling a business at approximately one times the revenue it gives up, collecting the money at $500,000 a year, from its own managers, with no disclosed fairness opinion.
Now the clause that made me stop:
"for every payment by the Purchaser of $1,000,000 of the principal... the cost plus markup percentage for products supplied to LightPath shall automatically increase by five percent (5%)... Upon full payment... fixed at cost plus thirty percent (30%)"
The supply agreement starts at cost plus ten percent. Every million dollars the buyer repays raises the price LightPath pays for its own products by five points. Stepped out, it looks like this:
The faster management pays LightPath for the factory, the worse LightPath's gross margin gets.
I want to be fair about this. There is a legitimate strategic reading. A company selling a China-substitution thesis while manufacturing in China has an obvious contradiction to resolve, and selling to the local management team who actually run the plant is a normal way to divest an operation that will not attract an arm's length buyer. Retaining supply, tooling and an observer seat is prudent.
But the ratchet is not standard, the counterparty includes insiders, no fairness opinion is disclosed, and the transaction has not closed yet. Those four facts belong in front of anyone underwriting this equity.
G5 is the company now, and the earnout tells you what it earned
LightPath bought G5 Infrared in February 2025. G5 makes cooled and uncooled thermal cameras. Camera level integration carries better margins than selling lens elements to somebody else who builds the camera.
G5's financial performance is never separately disclosed. But the earnout structure is disclosed, and the earnout can be solved backwards. This is the most useful piece of arithmetic in the file.
Start with the base year. The purchase agreement contained a clawback equal to 50 percent of any shortfall below $17.3 million of calendar 2024 revenue. The annual report shows a revenue clawback of $1,104,471. So $17,300,000 minus twice $1,104,471 gives $15,091,058. G5 did $15.09 million of revenue in calendar 2024. That number appears nowhere in any filing. It falls out of the clawback.
Then year one. The earnout ladder paid $3.5 million above $21 million of revenue, $7.0 million above $23 million, $10.5 million above $25 million and $14.0 million above $27 million. In the quarter ended March 31, 2026, LightPath paid $7.3 million in cash plus 297,445 shares worth $3.2 million. Exactly $10.5 million. That is the third tier.
Then year two, and this is the tell. The ladder pays $4.5 million above $30 million and $9.0 million above $33 million. On April 16, 2026, LightPath signed a side letter fixing year two at the maximum $9.0 million, ten and a half months before the measurement period even ends and four and a half months earlier than the contract required payment.
You do not agree to pay the top tier early unless you already know you are hitting it.
That is de facto forward guidance of G5 revenue above $33 million, disclosed in a contingent consideration footnote instead of a press release.
What it actually cost. All in, G5 is roughly $43.1 million rather than the $27.1 million headline, of which about $32.3 million is cash. The sellers collect $19.5 million of a possible $23.0 million of earnout, or 84.8 percent. That is a business bought well if the growth holds and expensively if it does not.
Why the reported loss is mostly not a loss
The nine month fiscal 2026 net loss is $16,404,698. That is the number a screener shows you and it looks awful for a company this size. Inside it is $12,234,529 of change in fair value of acquisition liabilities, which is the earnout being marked up because G5 keeps beating its tiers.
Strip it out and the underlying loss is about $4.17 million, with an underlying operating loss near $3.12 million. Quarter by quarter, excluding the mark, that loss narrows every single period:
That is a completely different picture from a $16.4 million hole.
Here is the elegant, perverse part. The better G5 performs, the larger the reported GAAP loss becomes, because the earnout liability marks up. Anyone screening this company on GAAP net income is being shown a number that gets worse as the business gets better.
The earnout liability trajectory is the cleanest public scorecard on a subsidiary that is otherwise invisible:
The jump in the December quarter is the moment G5 blew through its tiers.
The thing happening in about 48 hours
The June 3, 2026 offering carried twin sixty day restrictions that expire on or about August 2, 2026.
The first is a lock-up on all directors and executive officers and on North Run Strategic Opportunities Fund I, LP. North Run's residual 6,717,376 shares, 9.6 percent of the company, become saleable.
The second is LightPath's own restriction on issuing stock or convertibles, including the ban on variable rate transactions. The company becomes free to raise again, directly into the fiscal 2026 annual report window, which historically lands in late September.
I am not predicting either happens. I am telling you the doors open this week, and that a 9.6 percent holder becoming free to sell is the kind of thing that later gets attributed to news.
The order book, which is bigger than the press releases and is in the filings
Correction, added 31 July 2026. An earlier version of this piece said the backlog could not be verified from financial statements and that anyone quoting an order figure was quoting a press release. That was wrong, and a paid subscriber who has held the stock over a year and visited the Orlando facility corrected me within hours of publication. LightPath discloses backlog in MD&A as a named key indicator, with a five quarter table. I looked in the wrong part of the document. The corrected section follows, and the real number is much better than the one I used.
From the quarterly report for the period ended 31 March 2026, verbatim:
"Our total backlog at March 31, 2026 was approximately $110.6 million, an increase of 196%, as compared to $37.4 million as of June 30, 2025."
That is $110.6 million of firm orders against a business that did roughly $45 million of revenue in the trailing year. It is not a press release number, it is management discussion in a filed report, and the company defines it tightly: firm orders reasonably believed to remain in the backlog and convert to revenue, including customer purchase orders and qualifying supply contracts.
The composition matters more than the total.
Read the first line again. Fifty eight million dollars of it comes from "a leading global technology customer" for advanced infrared camera systems shipping in calendar 2026 and 2027. Not a defense prime. A technology company. I had assumed the large camera orders were a prime contractor buying for a military programme, and the filing says otherwise. Whoever that customer is, they are more than half the backlog, which is both the strongest fact in the bull case and the single largest concentration risk in the company.
There is also a third acquisition I had not found. LightPath closed on Amorphous Materials LLC on 21 January 2026. Amorphous Materials makes chalcogenide glass. So the company whose own annual report concedes that BD6 is generic went and bought one of the other producers of it. That is a direct answer to the objection I raised earlier in this piece, and it is a better answer than anything in the marketing.
And in the engineering services line, the filing names a Visimid development contract with Lockheed Martin. That is a real prime relationship, disclosed, currently small enough that its timing moves the segment around.
On the federal contract data, the original point still stands and is worth keeping. LightPath has approximately $1.0 million of lifetime federal prime contracts across six awards. It is a subcontractor. Its product goes into somebody else's camera. Prime to subcontractor purchase orders are not public, so USASpending will never show you this book. The mistake I made was concluding that therefore nothing was verifiable. The company reports it directly; you just have to read the management discussion rather than the contract database.
One research note for anyone following this trail. A plain search for LIGHTPATH in federal contract data returns about thirty awards, but most of them belong to a completely different company, the Lightpath fibre business selling internet circuits to the DEA, the FBI and the Maritime Administration. Filter to LIGHTPATH TECHNOLOGIES or you will overstate the defense footprint by roughly sixty percent.
Where I come out
I am not taking a position today. Here is the honest reason.
The company is more interesting than its story. The real moat, domestic melt plus a government-funded qualification path plus moulding yield plus camera integration, is more durable than the germanium narrative that got people here, and buying Amorphous Materials in January strengthens it further. G5 is compounding fast enough that management pre-committed to its maximum earnout. Backlog is $110.6 million against roughly $45 million of trailing revenue and it is disclosed, not asserted. The underlying loss is a quarter of the reported one and shrinking. The at-the-market facility is off.
Against that, a related party sale of the China factory to management with a margin ratchet and no fairness opinion, a 9.6 percent holder coming unlocked this week, a fresh ability to issue equity in the same window, more than half the backlog resting on one unnamed customer, and a central marketing claim the company's own annual report contradicts.
Those are not disqualifying. They are the reason to do the second half of the work before putting money down rather than after.
What Part 2 has to answer
Does the China sale close on these terms. No completion has been filed. Terms can change and the market has priced none of this.
Fiscal 2026 full year numbers. The year ended June 30. The annual report lands around late September and will carry the first clean full year view with G5 and AML in it, plus the June backlog figure.
Whether North Run sells. Ownership filings after August 2 answer that quickly.
Segment margins, camera versus component, separately. The entire vertical integration thesis rests on cameras being structurally better and nobody has shown the split.
Who the customer is. One unnamed leading global technology customer accounts for roughly $58 million of a $110.6 million backlog. Identifying it is the single highest value open question in this name, and the fact that it is a technology company rather than a defense prime narrows the field considerably.
Where the glass gets melted after the divestiture, and what the cost plus ratchet does to gross margin at each repayment step, modelled out.
What Amorphous Materials actually brings. LightPath bought a chalcogenide glass producer in January. Price, capacity, customer list, and whether it closes the generic-material gap or simply adds volume.
And the competitive question that decides the thesis. If VITRON and SCHOTT already make the same composition, what stops a US licensee of either from qualifying domestically. The answer is probably the qualification timeline. I want that timeline quantified in years.
Part 2 carries the model. This one is the map, and the map has a few roads on it that are not on anyone else's.
No position at time of writing. Not investment advice. Every figure sourced below and dated.
References
LightPath Technologies Form 10-K fiscal 2025, SEC CIK 0000889971, accession 0001654954-25-011130, Item 1 and Note 3
Form 10-Q, quarter ended 31 March 2026, accession 0001437749-26-015594, Note 4 and segment reconciliation
Form 8-K, 23 July 2026, accession 0001437749-26-024234, Item 1.01 and Exhibit 99.1, China divestiture
Form 8-K, 3 June 2026, accession 0001437749-26-019435, Item 1.01, offering and lock-up
Membership Interest Purchase Agreement, G5 Infrared, Exhibit 10.1 to 8-K accession 0001654954-25-001429, sections 2.8(b) and 2.8(c)
Post-effective amendments, accessions 0001437749-26-024147 through 0001437749-26-024176, and EFFECT 9999999995-26-002408
Registration statement 333-262768, A.G.P. and Alliance Global Partners at-the-market facility
USASpending prime award records, recipient LIGHTPATH TECHNOLOGIES, contracts SP800023P0004 and SP800024C0009
LightPath BD6 datasheet, Infrared Chalcogenide Glass As40Se60
VITRON Spezialwerkstoffe GmbH IG 6 specification and SCHOTT IRG series datasheets
Price and volume data, 30 July 2026, NASDAQ consolidated tape
So Part 2 comes after the annual report in late September?